Nivagen Pharmaceuticals LLC v. Sun Pharmaceuticals Industries, Inc.
3:25-cv-15210
Overview
Parties
Defendant
Sun Pharmaceutical Medicare Ltd. Operating Company
Represented By
0 Attorneys ListedSUN PHARMA ADVANCED RESEARCH COMPANY, LTD. Operating Company
Represented By
1 Attorneys ListedRIVKIN RADLER LLP
25 MAIN STREET, SUITE 501, COURT PLAZA NORTH
SUN PHARMACEUTICAL INDUSTRIES LTD Operating Company
Represented By
0 Attorneys ListedSUN PHARMACEUTICALS INDUSTRIES, INC. Operating Company
Represented By
3 Attorneys ListedRIVKIN RADLER, LLP
NEW JERSEY, 25 MAIN STREET, COURT PLAZA NORTH, SUITE 501
RIVKIN RADLER LLP
25 MAIN STREET, SUITE 501, COURT PLAZA NORTH
Plaintiff
NIVAGEN PHARMACEUTICALS LLC Operating Company
Represented By
8 Attorneys ListedMCCARTER & ENGLISH, LLP
FOUR GATEWAY CENTER, 100 MULBERRY STREET
UPADHYE TANG, LLP
COUNSEL NOT ADMITTED TO USDC - NJ BAR, 109 SYMONDS DRIVE, #174
UPADHYE TANG, LLP
COUNSEL NOT ADMITTED TO USDC - NJ BAR, 109 SYMONDS DRIVE, # 174
UPADHYE TANG, LLP
COUNSEL NOT ADMITTED TO USDC - NJ BAR, 109 SYMONDS DRIVE, #174
MCCARTER & ENGLISH, LLP
FOUR GATEWAY CENTER, 100 MULBERRY STREET
Court & Judges
Court
District Court, D. New Jersey (njd)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360° Radar 4 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| 🇺🇸 United States | Asserted | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → |
Sun Pharmaceutical Industries, Inc. v. Nivagen Pharmaceuticals, Inc.
Patents Involved
There is a single patent involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US11406598
Lyophilized compositions of phenobarbital sodium salt
|
Filed: 2020-09-18
Issued: 2022-08-09
|
Active (13.8 yrs remaining)
Expires: 2040-09-18
|
Patent Enforceability & Injunction Risk Assessment
Active Threat — Patent is within enforceable statutory term; injunctive relief viable.
Standard Statutory Term — No obviousness-type double patenting noted.
Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. 4th Year Maintenance Fee Paid (8th Year Window Upcoming).
Procedural Motions & Interlocutory Orders
Total Motions
38
Dispositive
10
Granted
9
Denied
0
Pending / Review
25
Motions by Category
Key Dispositive Motions & Rulings